Melanoma Treatment: Vemurafenib, Cobimetinib, and Atezolizumab

We are studying a combination of three medications for patients with high-risk melanoma to see if it helps achieve a complete response. We also want to understand its effects on survival and safety.

Efficacy phase (II)No Placebo Standard Medicines Oral InjectionDermatologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Zelboraf

Zelboraf is a medicine used to treat melanoma (a type of skin cancer) that has spread and has a specific gene change.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Atezolizumab

Atezolizumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein called PD-L1.

Cobimetinib

Cobimetinib is a substance that blocks a cell growth pathway to help treat certain types of cancer, especially melanoma with a BRAF mutation.

Vemurafenib

Vemurafenib is a substance that targets a specific BRAF mutation to slow growth of certain cancers, especially advanced melanoma.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

IRCCS Ospedale Policlinico San Martino

Divisione di Oncologia Medica 2

Genoa, Italy

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Oncologia

Meldola, Italy

Fondazione IRCCS Istituto Nazionale Dei Tumori

Medicina Oncologica/Medicina Oncologica 1

Milan, Italy

Sponsor: Fondazione Melanoma Onlus

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.